The strong preliminary efficacy and safety signal for ERAS-0015 positions it as a potential best-in-class pan-RAS inhibitor, significantly de-risking the program. Traders should watch for next data milestones (BOREALIS-1 2H 2026, AURORAS-1 expansion 1H 2027) and any partnership/licensing interest. The stock likely re-rates higher on this data.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 28 $9.90entry
- T+1 · 7mo ago −6.41%α −6.40% · $9.27
- T+5 · 7mo ago +2.42%α +0.73% · $10.14
- T+20 · 6mo ago +16.16%α +10.69% · $11.50
- T+60 · 4mo ago +95.35%α +91.36% · $19.34
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca announced positive preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing robust monotherapy response rates in KRAS G12X NSCLC (62% uORR8wk at PADs) and PDAC (40% uORR14wk) that exceeded comparator RMC-6236 by 24 and 11 percentage points, respectively. The data also demonstrated favorable safety with no DLTs and durable responses, supporting advancement into expansion cohorts ahead of schedule.
Key Facts
- ERAS-0015 achieved 62% uORR8wk at PADs in 2L+ KRAS G12X NSCLC (N=37), exceeding comparator RMC-6236 by 24 percentage points.
- In PDAC, 40% uORR14wk at PADs (N=20) exceeded comparator by 11 percentage points.
- No DLTs observed; mostly low-grade AEs with no discontinuations due to TRAEs.
- Monotherapy RDEs set at 24 mg and 32 mg QD; combination dose escalation with panitumumab initiated.
- Upcoming catalysts: AURORAS-1 expansion/combination data 1H 2027; BOREALIS-1 Phase 1 data 2H 2026.
Financial Impact
No financial figures provided; the data supports pipeline value but does not change near-term financials.
Risk Factors
- Preliminary data may not replicate in larger Phase 2/3 trials.
- Cross-study comparisons with RMC-6236 are not head-to-head and may be confounded by trial design differences.
- Competition from other RAS inhibitors (Revolution Medicines, etc.) could limit commercial potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-182137 |
| Document: 0001193125-26-182137-index-headers.html | 0001193125-26-182137 |
| Document: 0001193125-26-182137-index.html | 0001193125-26-182137 |
| Document: 0001193125-26-182137.txt | 0001193125-26-182137 |
Track record
26 reports on ERAS
3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers